- Home
- NUVB
NUVB
Nuvation Bio Inc.
as 01-21-2025 4:00pm EST
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 959.2M | IPO Year: | N/A |
| Target Price: | $7.00 | AVG Volume (30 days): | 2.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.23 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.52 - $4.16 | Next Earning Date: | 02-27-2025 |
| Revenue: | $2,162,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 369.72% |
Latest Nuvation Bio Inc. News
NUVB Breaking Stock News: Dive into NUVB Ticker-Specific Updates for Smart Investing
MT Newswires
15 days ago
RBC Raises Price Target on Nuvation Bio to $10 From $6, Keeps Outperform, Speculative Risk
Business Wire
15 days ago
Nuvation Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference
MT Newswires
16 days ago
Nuvation Bio's Taletrectinib Secures Approval in China for Lung Cancer Treatment
Business Wire
16 days ago
Nuvation Bio Receives Approval from China’s National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer
Insider Monkey
22 days ago
Why Is Nuvation Bio (NUVB) the Best Biotech Penny Stock to Invest in Now?
MT Newswires
a month ago
Sector Update: Health Care Stocks Fall Premarket Monday
MT Newswires
a month ago
Nuvation Bio's Lung Cancer Drug Candidate Taletrectinib Gets FDA Priority Review
Business Wire
a month ago
U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio’s New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung Cancer
Compare NUVB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NUVB Nuvation Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.